Hanmi's New Story
Creativity, Innovation, and Challenge
A New Era Takes Off at Hanmi
Meet Us at ObesityWeek 2025.
HM17321 Promotes High-Quality Weight Loss and Improves Metabolic Health in Obesity Treatment
- Presentation Number
- 105
- Session
- Poster Session, Nov. 4 at 19:30~20:30 PM, GWCC-Exhibit Hall A1
- Presenter
-
Eunseon Kim, Ph.D /
Hanmi Pharm Co., Ltd.
Efficacy and Safety of HM15275, a Novel Long-Acting Triple Agonist in Adults With Obesity
- Presentation Number
- 218
- Session
- Poster Session, Nov. 4 at 19:30~20:30 PM, GWCC-Exhibit Hall A1
- Presenter
-
JaeDuk Choi, Ph.D /
Hanmi Pharm Co., Ltd.
Discovery of HM17321: A Novel CRFR2 Selective and Biased UCN2 Analog for High-Quality Weight Loss
- Presentation Number
- 320
- Session
- Poster Session, Nov. 5 at 14:30~15:30 PM, GWCC-Exhibit Hall A1
- Presenter
-
Seungsu Han, Ph.D /
Hanmi Pharm Co., Ltd.
Blood and Muscle Proteomic Analysis Reveals Muscle-Preserving Effects of HM17321 in Mouse Model
- Presentation Number
- 571
- Session
- Poster Session, Nov. 6 at 14:30~15:30 PM, GWCC-Exhibit Hall A1
- Presenter
-
Boram Kim, Ph.D /
Hanmi Pharm Co., Ltd.
Meet Us at SITC 2025.
Identifying predictive biomarkers for HM16390, a novel long-acting IL-2 analog, by analyzing single -cell and bulk transcriptomic data of immune checkpoint inhibitors treated patients
- Presentation Number
- 137
- Session
- Poster (Biomarkers, Immune Monitoring and Novel Technologies), Nov. 7 at 12:15~13:45 PM, Prince George ABC Exhibit Halls
- Presenter
-
Yu-Yon Kim, Ph.D /
Hanmi Pharm Co., Ltd.
A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM16390, as a Single Agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
- Presentation Number
- 539
- Session
- Poster (Clinical Trials In Progress), Nov. 7 at 12:15~13:45 PM, Prince George ABC Exhibit Halls
- Presenter
-
Jong Chul Park, M.D, Ph.D /
Massachusetts General Hospital
Subin Kim, Ph.D /
Hanmi Pharm Co., Ltd.
HM16390, a long-acting IL-2 analog with enhanced IL-2Rβ and optimal IL-2Rα bindings, promotes peripheral Treg expansion to mitigate systemic toxicity while preserving potent anti-tumor immunity
- Presentation Number
- 859
- Session
- Poster (Immune-stimulations and immune modulators), Nov. 7 at 12:15~13:45 PM, Prince George ABC Exhibit Halls
- Presenter
-
Jinyoung Kim /
Hanmi Pharm Co., Ltd.
HM16390, a long-acting IL-2 analog with enhanced IL-2Rβ binding and optimal IL-2Rα binding, selectively expands tumor-specific T cells, resulting in potent anti-tumor immunity in murine tumor models
- Presentation Number
- 850
- Session
- Poster (Immune-stimulations and immune modulators), Nov. 8 at 12:15~13:45 PM, Prince George ABC Exhibit Halls
- Presenter
-
Jaehyuk Choi, Ph.D /
Hanmi Pharm Co., Ltd.
